Press Releases

Press Releases

Date Title Views
November 16, 2019
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated
October 31, 2019
SAN FRANCISCO , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the company’s recent
September 30, 2019
  SAN FRANCISCO , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced that an interim analysis of its ongoing
September 19, 2019
SAN FRANCISCO , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3 rd at 3:00 p.m. EDT in New York, NY .
September 12, 2019
Advises Stockholders Take No Action at this Time SAN FRANCISCO --(BUSINESS WIRE)--Sep. 12, 2019-- Eidos Therapeutics, Inc. (Nasdaq:EIDX) (“Eidos”) announced today that the Special Committee of its Board of Directors (the “Special Committee”) unanimously rejected the non-binding proposal dated
September 9, 2019
- Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe ; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 - - Agreement expands Alexion’s amyloidosis portfolio - -
August 12, 2019
Forms Special Committee of Independent and Disinterested Directors to Review Proposal Advises Stockholders Take No Action at this Time SAN FRANCISCO --(BUSINESS WIRE)--Aug. 12, 2019-- Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the “Company”) today confirmed that it has received a non-binding proposal
August 1, 2019
SAN FRANCISCO , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an update on the company’s recent achievements. “We remain focused on executing our Phase 3 program
June 18, 2019
SAN FRANCISCO , June 18, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25 th at 2:40 p.m. EDT in New York, NY .
May 7, 2019
SAN FRANCISCO , May 07, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company’s recent achievements. “The initiation of our Phase 3 ATTRibute-CM study in the
Displaying 1 - 10 of 18